1.Preparation and content determination of extended-release tablets of altrenogest
Yurou HUO ; Qi ZHAO ; Kai WANG ; Jianxu ZHANG ; Shiyao XU ; Jiabin ZHANG ; Yujie YANG ; Haiquan GU ; Qianxue LI ; Xiuxia HE
Chinese Journal of Veterinary Science 2024;44(6):1248-1255
This study aims to prepare altrenogest extended-release tablets,evaluate their quality and establish a content determination method.The hydrophilic gel skeleton type,dosage and core thick-ness of altrenogest extended-release tablets were used as the investigating factors,and the release degree of the tablets was used as the investigating index,the prescription process of altrenogest ex-tended-release tablets was optimized by one-factor screening and central combinatorial design re-sponse surface method,and quality evaluation was carried out,the in vitro release model was es-tablished,and a high-performance liquid chromatography(HPLC)assay method was set up for the determination of altrenogest extended-release tablets.The results showed that the optimal pre-scription of altrenogest extended-release tablets was 2%as the main drug,70%as the solubilizer,0.5%as the lubricant,19.1%as the filler,8.4%as the hydrophilic gel skeleton material,and the thickness of the tablets was 3.8 mm.The in vitro drug release conformed to the Higuchi model,and the altrenogest showed a good linear relationship with the R2=0.999 98 in the range of 10-80 mg/L.The optimized process for the extended-release tablets was stable and had a good quality.The extended-release tablets were stable and had significant slow-release effect.The HPLC method is accurate and reliable and can be used for the determination of altrenogest in extended-release tablets.
2.Formulation screening and content determination of compound albendazole sulfox-ide pouring agent
Qi ZHAO ; Yurou HUO ; Jianxu ZHANG ; Shiyao XU ; Jiabin ZHANG ; Bo LI ; Yufei WANG ; Yujie YANG ; Haiquan GU ; Kai WANG ; Qianxue LI
Chinese Journal of Veterinary Science 2024;44(10):2213-2220
Albendazole sulfoxide and ivermectin compound pouring agent were prepared with dime-thyl sulfoxide and 1,2-propanediol as solvents.The central composite design response surface method was used to optimize the formula of pouring agent.Franz diffusion cell method was used to investigate the transdermal performance of pouring agent in vitro.The permeation amounts of the two drugs were determined by HPLC.The best formula of pouring agent was ivermectin 0.5%,al-bendazole sulfoxide 5%,dimethyl sulfoxide 52%,propylene glycol 39%,and the rest was 100%anhydrous ethanol.The cumulative permeation amounts of ivermectin and albendazole sulfoxide were up to 20.78 μg/cm2 and 249.02 μg/cm2,respectively.The in vitro release model of the two drugs accords with the first-order kinetic equation.There is a good linear relationship between al-bendazole sulfoxide and ivermectin in the range of 1-100 mg/L and the peak area.The precision and stability RSD of the two methods are less than 2%.The preparation process of albendazole sul-foxide compound pouring agent is simple,stable and easy to pour.The established HPLC method is simple and accurate,and can be used for the determination of albendazole sulfoxide and ivermectin in pouring agent.